Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,074 across all filing types
Latest filing 2023-12-22 Regulatory Filings
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific financial event (an impairment charge) and a strategic business update regarding the withdrawal of market authorizations for a drug. It does not constitute a full financial report, nor is it a mere announcement of a report's publication. Since it details a specific corporate development and financial impact, it falls under the general regulatory announcement category for material events.
2023-12-22 English
Vivesto gör nedskrivning av tillgångar efter tillbakadragande av de europeiska marknadsföringstillstånden för Apealea
Earnings Release Classification · 100% confidence The document is a press release from Vivesto AB announcing a financial write-down of assets related to the product Apealea following the withdrawal of marketing authorizations. It provides details on the financial impact (43.2 million SEK) and strategic business updates. While it contains financial information, it is a specific corporate announcement rather than a full quarterly or annual report. It does not fit into specific categories like M&A or dividend notices, and it is a direct announcement of a material event, making it a general regulatory filing. FY 2023
2023-12-22 Swedish
Valberedning utsedd inför Vivestos årsstämma 2024
Board/Management Information Classification · 99% confidence The document is titled "Valberedning utsedd inför Vivestos årsstämma 2024" (Nomination Committee appointed ahead of Vivesto's Annual General Meeting 2024). It details the composition of the Nomination Committee based on ownership structure as of September 30, 2023, and announces the date of the upcoming Annual General Meeting (AGM) on May 23, 2024. This content directly relates to the preparation and governance surrounding the AGM. While it is an announcement, the core subject matter is the nomination committee structure, which is a key component of the AGM process. However, the definitions provided suggest that 'AGM Information' (AGM-R) covers presentations and materials shared *during* the AGM. The document is an announcement *before* the AGM regarding the committee responsible for nominations for the board, which is closely related to shareholder voting and governance leading up to the meeting. Given the options, this announcement about the committee selection for the AGM is best classified as related to the AGM process. If a more specific category existed for 'Nomination Committee Announcement', that would be ideal. Since the document is an announcement about the AGM process and governance structure leading up to it, and it is not a proxy statement (PSI) or a declaration of voting results (DVA), AGM-R is the most appropriate fit among the choices, as it pertains directly to the AGM setup. It is not a general regulatory filing (RNS) because a more specific context exists.
2023-11-23 Swedish
Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto
Board/Management Information Classification · 99% confidence The document explicitly announces the appointment of the Nomination Committee for the upcoming 2024 Annual General Meeting (AGM) and provides details about the committee members and the AGM date (May 23, 2024). This content directly relates to the preparatory materials and governance surrounding the AGM. While it mentions the AGM, it is not the AGM presentation itself (AGM-R), nor is it a proxy statement (PSI) or a general board change announcement (MANG). It is a specific announcement regarding the committee responsible for nominations ahead of the AGM. Given the options, this falls under general governance/meeting preparation, but the most specific fit related to the AGM process, especially concerning nominations, is often grouped with AGM materials or governance. However, since the core subject is the *appointment* of a committee *for* the AGM, and it is a specific announcement, it aligns best with the general scope of AGM-related information or governance. Since there is no specific code for 'Nomination Committee Appointment', and it is a formal announcement related to the AGM structure, AGM-R (AGM Information) is the closest fit, as these announcements precede the meeting itself. Alternatively, it could be seen as Governance Information (CGR). Given the direct reference to the 'Annual General Meeting' multiple times, AGM-R is prioritized over the broader CGR.
2023-11-23 English
Vivesto and Elevar sign agreement ending Apealea® partnership
M&A Activity Classification · 99% confidence The document is a press release announcing the termination of a strategic partnership between Vivesto and Elevar Therapeutics regarding the commercialization of Apealea®. It details the financial compensation, transfer of rights, and future plans. The text concludes with a statement that the information is 'obliged to make public pursuant to the EU Market Abuse Regulation' and includes an attachment link. This structure—a brief announcement of a significant corporate event (partnership termination/change in commercial rights) that is legally required to be disclosed—fits best under the general 'Regulatory Filings' category (RNS) or potentially a specific corporate action category. Since it is not a formal financial report (10-K, IR, ER), nor a management change (MANG), nor a capital change (CAP/SHA), the most appropriate general regulatory disclosure category for non-standard, mandatory announcements is RNS (Regulatory Filings). Given the document length is short (3977 chars) and it announces the publication of an attachment, it could also be considered an RPA, but RNS is often used for mandatory market disclosures like this under EU regulations.
2023-11-23 English
Vivesto och Elevar tecknar avtal för att avsluta partnerskap rörande Apealea®
Legal Proceedings Report Classification · 99% confidence The document is a press release dated November 23, 2023, announcing the termination of a strategic partnership regarding the cancer product Apealea®. It details the financial settlement ($500,000 USD) and the transfer of market authorization rights. The text concludes with a statement: "Denna information är sådan information som Vivesto AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Vivesto AB is obliged to make public according to the EU Market Abuse Regulation). This strongly indicates a mandatory regulatory disclosure. Since it is an announcement about a significant business event (termination of a major agreement) and not a full periodic report (10-K, IR) or a specific transaction report (DIV, DIRS, SHA), it fits best under the general regulatory announcement category, which is RNS (Regulatory Filings). The document length is short (3699 chars) and it announces information rather than being the full report itself, ruling out classifications like 10-K or IR.
2023-11-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.